Nektar Therapeutics Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Nektar Therapeutics (NKTR) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $237.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-14
- Nektar Therapeutics proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $136.44M, a 98.97% increase year-over-year.
- Nektar Therapeutics proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $101.48M, a 46.40% increase year-over-year.
- Nektar Therapeutics proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $91.99M, a 41.28% increase year-over-year.
- Nektar Therapeutics proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $54.80M, a 15.90% decline year-over-year.
- Nektar Therapeutics proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $284.68M, a 16.36% decline from fiscal 2024.
- Nektar Therapeutics proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $340.36M, a 47.71% decline from fiscal 2023.
- Nektar Therapeutics proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $650.88M, a 21.22% decline from fiscal 2022.
- Nektar Therapeutics proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $826.23M, a 29.20% decline from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $136.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $237.92M 10-Q · filed 2026-08-14 | $329.91M derived: sum of 3 quarters · filed 2026-08-14 | $384.71M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $101.48M 10-Q · filed 2026-05-08 | $193.47M derived: sum of 2 quarters · filed 2026-05-08 | $248.27M derived: sum of 3 quarters · filed 2026-05-08 | $316.85M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $91.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $146.79M derived: sum of 2 quarters · filed 2026-03-13 | $215.36M derived: sum of 3 quarters · filed 2026-08-14 | $284.68M 10-K · filed 2026-03-13 |
| 2025-09-30 | $54.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $123.37M derived: sum of 2 quarters · filed 2026-08-14 | $192.69M 10-Q · filed 2025-11-07 | $257.81M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $68.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $137.89M 10-Q · filed 2026-08-14 | $203.01M derived: sum of 3 quarters · filed 2026-08-14 | $268.17M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $69.32M 10-Q · filed 2026-05-08 | $134.43M derived: sum of 2 quarters · filed 2026-05-08 | $199.59M derived: sum of 3 quarters · filed 2026-05-08 | $285.21M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $65.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $130.27M derived: sum of 2 quarters · filed 2026-03-13 | $215.89M derived: sum of 3 quarters · filed 2026-03-13 | $340.36M 10-K · filed 2026-03-13 |
| 2024-09-30 | $65.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $150.77M derived: sum of 2 quarters · filed 2025-11-07 | $275.25M 10-Q · filed 2025-11-07 | $431.75M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $85.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $210.09M 10-Q · filed 2025-08-08 | $366.58M derived: sum of 3 quarters · filed 2025-08-08 | $544.88M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $124.47M 10-Q · filed 2025-05-09 | $280.97M derived: sum of 2 quarters · filed 2025-05-09 | $459.27M derived: sum of 3 quarters · filed 2025-05-09 | $627.31M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $156.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $334.80M derived: sum of 2 quarters · filed 2025-03-14 | $502.84M derived: sum of 3 quarters · filed 2025-03-14 | $650.88M 10-K · filed 2025-03-14 |
| 2023-09-30 | $178.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $346.34M derived: sum of 2 quarters · filed 2024-11-08 | $494.38M 10-Q · filed 2024-11-08 | $694.19M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $168.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $316.09M 10-Q · filed 2024-08-09 | $515.89M derived: sum of 3 quarters · filed 2024-08-09 | $675.89M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $148.04M 10-Q · filed 2024-05-10 | $347.85M derived: sum of 2 quarters · filed 2024-05-10 | $507.85M derived: sum of 3 quarters · filed 2024-05-10 | $746.30M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $199.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $359.81M derived: sum of 2 quarters · filed 2024-03-05 | $598.25M derived: sum of 3 quarters · filed 2024-03-05 | $826.23M 10-K · filed 2024-03-05 |
| 2022-09-30 | $160.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $398.45M derived: sum of 2 quarters · filed 2023-11-08 | $626.42M 10-Q · filed 2023-11-08 | $890.69M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $238.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $466.42M 10-Q · filed 2023-08-09 | $730.69M derived: sum of 3 quarters · filed 2024-03-05 | $1.02B derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $227.97M 10-Q · filed 2023-05-10 | $492.24M derived: sum of 2 quarters · filed 2024-03-05 | $782.51M derived: sum of 3 quarters · filed 2024-03-05 | $1.09B derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $264.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $554.53M derived: sum of 2 quarters · filed 2024-03-05 | $863.34M derived: sum of 3 quarters · filed 2024-03-05 | $1.17B 10-K · filed 2024-03-05 |
| 2021-09-30 | $290.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $599.08M derived: sum of 2 quarters · filed 2022-11-04 | $902.69M 10-Q · filed 2022-11-04 | $1.19B derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $308.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $612.42M 10-Q · filed 2022-08-05 | $903.00M derived: sum of 3 quarters · filed 2023-02-28 | $1.20B derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $303.61M 10-Q · filed 2022-05-06 | $594.19M derived: sum of 2 quarters · filed 2023-02-28 | $892.59M derived: sum of 3 quarters · filed 2023-02-28 | $1.31B derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $290.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $588.97M derived: sum of 2 quarters · filed 2023-02-28 | $1.01B derived: sum of 3 quarters · filed 2023-02-28 | $1.45B 10-K · filed 2023-02-28 |
| 2020-09-30 | $298.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $718.99M derived: sum of 2 quarters · filed 2021-11-05 | $1.16B 10-Q · filed 2021-11-05 | $1.65B derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $420.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $860.33M 10-Q · filed 2021-08-06 | $1.35B derived: sum of 3 quarters · filed 2022-03-01 | $1.84B derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $439.74M 10-Q · filed 2021-05-07 | $930.87M derived: sum of 2 quarters · filed 2022-03-01 | $1.42B derived: sum of 3 quarters · filed 2022-03-01 | $1.69B derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $491.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $979.89M derived: sum of 2 quarters · filed 2022-03-01 | $1.25B derived: sum of 3 quarters · filed 2022-03-01 | $1.61B 10-K · filed 2022-03-01 |
| 2019-09-30 | $488.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $760.65M derived: sum of 2 quarters · filed 2020-11-06 | $1.12B 10-Q · filed 2020-11-06 | $1.55B derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $271.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $634.14M 10-Q · filed 2020-08-07 | $1.06B derived: sum of 3 quarters · filed 2021-02-26 | $1.39B derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $362.25M 10-Q · filed 2020-05-08 | $785.55M derived: sum of 2 quarters · filed 2021-02-26 | $1.12B derived: sum of 3 quarters · filed 2021-02-26 | $1.22B derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $423.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $758.18M derived: sum of 2 quarters · filed 2021-02-26 | $853.73M derived: sum of 3 quarters · filed 2021-02-26 | $890.96M 10-K · filed 2021-02-26 |
| 2018-09-30 | $334.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $430.43M derived: sum of 2 quarters · filed 2019-11-07 | $467.66M 10-Q · filed 2019-11-07 | $554.29M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $95.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $132.78M 10-Q · filed 2019-08-09 | $219.41M derived: sum of 3 quarters · filed 2020-02-28 | $332.96M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $37.23M 10-Q · filed 2019-05-09 | $123.86M derived: sum of 2 quarters · filed 2020-02-28 | $237.42M derived: sum of 3 quarters · filed 2020-02-28 | $326.92M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $86.63M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $200.19M derived: sum of 2 quarters · filed 2020-02-28 | $289.69M derived: sum of 3 quarters · filed 2020-02-28 | $347.74M 10-K · filed 2020-02-28 |
| 2017-09-30 | $113.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $203.06M derived: sum of 2 quarters · filed 2018-11-08 | $261.11M 10-Q · filed 2018-11-08 | $313.35M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $89.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $147.56M 10-Q · filed 2018-08-09 | $199.79M derived: sum of 3 quarters · filed 2019-03-01 | $293.88M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $58.05M 10-Q · filed 2018-05-10 | $110.29M derived: sum of 2 quarters · filed 2019-03-01 | $204.37M derived: sum of 3 quarters · filed 2019-03-01 | $242.36M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $52.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $146.32M derived: sum of 2 quarters · filed 2019-03-01 | $184.31M derived: sum of 3 quarters · filed 2019-03-01 | $253.68M 10-K · filed 2019-03-01 |
| 2016-09-30 | $94.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $132.07M derived: sum of 2 quarters · filed 2017-11-08 | $201.45M 10-Q · filed 2017-11-08 | $272.69M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $37.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $107.36M 10-Q · filed 2017-08-09 | $178.60M derived: sum of 3 quarters · filed 2018-03-01 | $223.28M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $69.38M 10-Q · filed 2017-05-10 | $140.62M derived: sum of 2 quarters · filed 2018-03-01 | $185.30M derived: sum of 3 quarters · filed 2018-03-01 | $222.87M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $71.24M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $115.92M derived: sum of 2 quarters · filed 2018-03-01 | $153.49M derived: sum of 3 quarters · filed 2018-03-01 | $226.92M 10-K · filed 2018-03-01 |
| 2015-09-30 | $44.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $82.25M derived: sum of 2 quarters · filed 2016-11-04 | $155.68M 10-Q · filed 2016-11-04 | $231.85M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $37.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $111.00M 10-Q · filed 2016-08-04 | $187.17M derived: sum of 3 quarters · filed 2017-03-01 | $240.22M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $73.43M 10-Q · filed 2016-05-04 | $149.60M derived: sum of 2 quarters · filed 2017-03-01 | $202.65M derived: sum of 3 quarters · filed 2017-03-01 | $264.46M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $76.17M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $129.22M derived: sum of 2 quarters · filed 2017-03-01 | $191.02M derived: sum of 3 quarters · filed 2017-03-01 | $248.00M 10-K · filed 2017-03-01 |
| 2014-09-30 | $53.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $114.85M derived: sum of 2 quarters · filed 2015-11-06 | $171.83M 10-Q · filed 2015-11-06 | $217.00M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $61.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $118.78M 10-Q · filed 2015-08-06 | $163.95M derived: sum of 3 quarters · filed 2016-02-29 | $237.48M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $56.97M 10-Q · filed 2015-05-01 | $102.14M derived: sum of 2 quarters · filed 2016-02-29 | $175.68M derived: sum of 3 quarters · filed 2016-02-29 | $275.81M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $45.17M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $118.70M derived: sum of 2 quarters · filed 2016-02-29 | $218.84M derived: sum of 3 quarters · filed 2016-02-29 | $319.18M 10-K · filed 2016-02-29 |
| 2013-09-30 | $73.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $173.67M derived: sum of 2 quarters · filed 2014-11-07 | $274.01M 10-Q · filed 2014-11-07 | $379.13M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $100.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | $200.48M 10-Q · filed 2014-08-01 | $305.60M derived: sum of 3 quarters · filed 2015-02-26 | $328.60M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $100.34M 10-Q · filed 2014-05-08 | $205.46M derived: sum of 2 quarters · filed 2015-02-26 | $228.46M derived: sum of 3 quarters · filed 2015-02-26 | $256.26M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $105.12M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $128.12M derived: sum of 2 quarters · filed 2015-02-26 | $155.92M derived: sum of 3 quarters · filed 2015-02-26 | $307.89M 10-K · filed 2015-02-26 |
| 2012-09-30 | $23.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $50.80M derived: sum of 2 quarters · filed 2013-11-07 | $202.77M 10-Q · filed 2013-11-07 | $295.01M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $27.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $179.77M 10-Q · filed 2013-08-09 | $272.01M derived: sum of 3 quarters · filed 2014-02-27 | $405.86M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $151.96M 10-Q · filed 2013-05-09 | $244.21M derived: sum of 2 quarters · filed 2014-02-27 | $378.05M derived: sum of 3 quarters · filed 2014-02-27 | $421.78M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $92.24M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $226.09M derived: sum of 2 quarters · filed 2014-02-27 | $269.82M derived: sum of 3 quarters · filed 2014-02-27 | $383.05M 10-K · filed 2014-02-27 |
| 2011-09-30 | $133.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $177.57M derived: sum of 2 quarters · filed 2012-11-09 | $290.81M 10-Q · filed 2012-11-09 | $405.72M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $43.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $156.96M 10-Q · filed 2012-08-09 | $271.87M derived: sum of 3 quarters · filed 2013-03-01 | $391.52M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $113.23M 10-Q · filed 2012-05-04 | $228.14M derived: sum of 2 quarters · filed 2013-03-01 | $347.79M derived: sum of 3 quarters · filed 2013-03-01 | $476.97M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $114.91M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $234.56M derived: sum of 2 quarters · filed 2013-03-01 | $363.74M derived: sum of 3 quarters · filed 2013-03-01 | $475.81M 10-K · filed 2013-03-01 |
| 2010-09-30 | $119.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $248.83M derived: sum of 2 quarters · filed 2011-11-04 | $360.91M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $129.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | $241.26M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | $112.07M 10-Q · filed 2011-04-29 | |||
| 2009-12-31 | $310.71M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |